A Clinical Trial to Evaluate Efficacy and Safety of Two Different Formulations of Topical Calcipotriol in Patients With Mild to Moderate Plaque Psoriasis
- Conditions
- Mild to Moderate Plaque Psoriasis
- Interventions
- Drug: Calcipotriol/AKVANO, 50 μg/g cutaneous solutionDrug: Calcipotriol Ointment 50 micrograms/gOther: Placebo
- First Posted Date
- 2022-01-03
- Last Posted Date
- 2022-03-03
- Lead Sponsor
- Cadila Pharnmaceuticals
- Target Recruit Count
- 278
- Registration Number
- NCT05174598
- Locations
- 🇮🇳
Midland Healthcare & Research Center, Lucknow, Uttar Pradesh, India
🇮🇳Postgraduate Institute of Medical Education and Research, Chandigarh, India
🇮🇳Government Medical College, Aurangabad, Maharashtra, India
Effect of CPL-2009-0031 in the Treatment of Patients With Uncontrolled Type 2 Diabetes Mellitus
- Conditions
- Uncontrolled Type 2 Diabetes Mellitus
- Interventions
- Drug: CPL-2009-0031 140 mgDrug: Sitagliptin 100mg
- First Posted Date
- 2021-03-16
- Last Posted Date
- 2021-08-17
- Lead Sponsor
- Cadila Pharnmaceuticals
- Target Recruit Count
- 355
- Registration Number
- NCT04801199
- Locations
- 🇮🇳
Life Line Diagnostic Centre cum Nursing Home, Kolkata, West Bengal, India
🇮🇳Sanjivini Lung Centre, Lucknow, Uttar Pradesh, India
🇮🇳Bangalore Diabetes Centre, Bangalore, Karnataka, India
Clinical Trial of Mycobacterium w in COVID-19 Positive Patients, Hospitalized But Not Critically Ill
- Conditions
- COVID-19
- Interventions
- First Posted Date
- 2020-04-24
- Last Posted Date
- 2020-12-22
- Lead Sponsor
- Cadila Pharnmaceuticals
- Target Recruit Count
- 480
- Registration Number
- NCT04358809
- Locations
- 🇮🇳
All India Institute of Medical Science, Raipur, Raipur, Chhattisgarh, India
🇮🇳All India Institute of Medical Sciences, Bhopal, Bhopal, India
🇮🇳All India Institute of Medical Sciences, Delhi, Delhi, India
Clinical Trial to Evaluate Mycobacterium w in Preventing COVID-19 in Subjects at Risk of Getting Infected With COVID-19
- Conditions
- COVID-19
- Interventions
- First Posted Date
- 2020-04-20
- Last Posted Date
- 2020-12-22
- Lead Sponsor
- Cadila Pharnmaceuticals
- Target Recruit Count
- 4000
- Registration Number
- NCT04353518
- Locations
- 🇮🇳
All India Institute of Medical Sciences, Bhopal, Bhopal, Madhya Pradesh, India
🇮🇳Post Graduate Institute of Medical Education and Research, Chandigarh, India
🇮🇳All lndia Institute of Medical Science, Delhi, Delhi, India
A Clinical Trial of Mycobacterium w in Critically Ill COVID 19 Patients
- Conditions
- COVID-19
- Interventions
- First Posted Date
- 2020-04-15
- Last Posted Date
- 2021-01-27
- Lead Sponsor
- Cadila Pharnmaceuticals
- Target Recruit Count
- 40
- Registration Number
- NCT04347174
- Locations
- 🇮🇳
All lndia Institute of Medical Science, Delhi, Delhi, India
🇮🇳Postgraduate Institute of Medical Education and Research, Chandigarh, India
🇮🇳All India Institute of Medical Sciences, Bhopal, Bhopal, Madhya Pradesh, India
Study of Mycobacterium w in BCG Refractory Superficial Transitional Cell Carcinoma of Bladder
- Conditions
- Bladder Cancer
- Interventions
- Biological: Mycobacterium w
- First Posted Date
- 2008-06-11
- Last Posted Date
- 2012-05-03
- Lead Sponsor
- Cadila Pharnmaceuticals
- Target Recruit Count
- 22
- Registration Number
- NCT00694798
- Locations
- 🇮🇳
Muljibhai Patel Urological Hospital, Nadiad, Gujrat, India
🇮🇳Lourdes Hospital, Kochi, Kerala, India
🇮🇳Choithram Hospital and Research Centre, Indore, Madhya Pradesh, India
Study of Mycobacterium w in Superficial Transitional Cell Carcinoma of Bladder
- Conditions
- Bladder Cancer
- Interventions
- Biological: BCG (Bacillus Calmette-Guerin)Biological: Mycobacterium w
- First Posted Date
- 2008-06-11
- Last Posted Date
- 2021-08-17
- Lead Sponsor
- Cadila Pharnmaceuticals
- Target Recruit Count
- 122
- Registration Number
- NCT00694915
- Locations
- 🇮🇳
N.R.R. Hospital, Bangalore, Karnataka, India
🇮🇳Dr. Ram Manohar Lohia Hospital & PGIMER, New Delhi, India
🇮🇳Indira Gandhi Medical College, Shimla, Himachal Pradesh, India
A Study of Mycobacterium w in Combination With Paclitaxel Plus Cisplatin in Advanced Non Small Cell Lung Cancer
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Drug: Paclitaxel & CisplatinBiological: Mycobacterium w.
- First Posted Date
- 2008-05-20
- Last Posted Date
- 2012-08-07
- Lead Sponsor
- Cadila Pharnmaceuticals
- Target Recruit Count
- 221
- Registration Number
- NCT00680940
- Locations
- 🇮🇳
Malabar Institute of Medical Science (MIMS), Calicut, Kerala, India
🇮🇳V.N. Cancer Center, GKNM Hospital, Coimbatore, TamilNadu, India
🇮🇳Patel Hospital Pvt. Ltd, Jalandhar, Punjab, India
Safety Study of CADI-05 in Patients With Advanced Stage Melanoma
- Conditions
- Stage III or Stage IV Melanoma
- First Posted Date
- 2008-05-12
- Last Posted Date
- 2009-06-11
- Lead Sponsor
- Cadila Pharnmaceuticals
- Target Recruit Count
- 20
- Registration Number
- NCT00675727
- Locations
- 🇺🇸
Lehigh Valley Hospital, Allentown, Pennsylvania, United States
A Study of Mycobacterium w Plus Docetaxel for Hormone Refractory Metastatic Prostate Cancer
- Conditions
- Hormone Refractory Prostate Cancer
- Interventions
- Biological: Mycobacterium w.Drug: Docetaxel
- First Posted Date
- 2007-09-05
- Last Posted Date
- 2012-03-12
- Lead Sponsor
- Cadila Pharnmaceuticals
- Target Recruit Count
- 134
- Registration Number
- NCT00525408
- Locations
- 🇮🇳
Regional Cancer Centre, Trivandrum, Kerala, India
🇮🇳Post Graduate Institute of Medical Education and Research, Chandigarh, India
🇮🇳V.M. Medical College & Safdarjang Hospital, New Delhi, Delhi, India